Blenrep Drug to Undo Certain Changes Performed by Multiple Myeloma Cancer in Patients

Release Date: 28-Nov-2020

There has been a rise in the unmet demands of the cancer patients towards having an efficient therapy for the treatment of relapsed multiple myeloma. But the approval of the drug called as Blenrep for the cancer patients is estimated to end all the demands of the cancer patients. According to the researchers involved in the respective clinical study, the drug not only is responsible for eliciting response in the patients who have developed resistance against different cancer types as well as the treatment is also responsible for developing durable response in the patients. Also, the drug has also shown safety profile in the patients.


The clinical trial study which led to the approval of the antibody drug conjugate for the cancer patients is called as DREAMM-2 study. The study was tested in the patients who have undergone cancer therapies already for the treatment of the cancer i.e. immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody. The overall response that was observed in the patients who were enrolled in the study was 32%.


The researchers inclined towards the research study are also focused towards combining different cancer therapies with this respective drug for achieving better durable response in the patients. Some of the drugs that are estimated to get combined with the approved drug in the future are: lenalidomide, bortezomib, and dexamethasone. The approval of the drug by the regulatory body is estimated to unmet the medical need of the patients suffering myeloma. It is estimated that the future research study with respect to the impact of the combination of the drug with other therapies will result in greater results such as high five -year survival rate and 100% complete response. The overall impact of the approved drug for the patient population is estimated to be deliver tons of hopes to the patients so that side effects and high mortality rate due to cancer could observe a decline.

Need custom market research solution? We can help you with that too.